WO2025010224 - INTRANASAL DELIVERY
National phase entry:
Publication Number
WO/2025/010224
Publication Date
09.01.2025
International Application No.
PCT/US2024/036371
International Filing Date
01.07.2024
Title **
[English]
INTRANASAL DELIVERY
[French]
ADMINISTRATION INTRANASALE
Applicants **
VIRPAX PHARMACEUTICALS INC.
1055 Westlakes Drive #300
Berwyn, PA 19312, US
Inventors
UCHEGBU, Ijeoma
1055 Westlakes Drive #300
Berwyn, PA 19312, US
SCHATZLEIN, Andreas
1005 Westlakes Drive #300
Berwyn, PA 19312, US
MACK, Anthony
1005 Westlakes Drive #300
Berwyn, PA 19312, US
MATHIAS, Sheila
1005 Westlakes Drive #300
Berwyn, PA 19312, US
Priority Data
63/524,764
03.07.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2221 | |
| EPO | Filing, Examination | 16268 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 8480 |
Total: 28139 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to formulations, devices and delivery of leucine-5-enkephalin (LENK) formulated with N-palmitoyl-N-acetyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQor Molecular Envelope Technology - MET). In particular, the present invention relates to delivering leucine-5-enkephalin encapsulated in GCPQ. intranasally via a drug or medicine dispersion and delivery system. The dispersion methods employ curved surfaces to impart rotational motions to one or more fluid flows from a pressurized container to create turbulence and improve mixing of medicament with fluid.[French]
La présente invention concerne des formulations, des dispositifs et l'administration de leucine-5-enképhaline (LENK) formulée avec du N-palmitoyl-N-acétyl-N-monométhyl-N,N-diméthyl-N,N,N-triméthyl-6-O-glycolchitosane (GCPQ ou Technologie d'enveloppe moléculaire - MET). En particulier, la présente invention concerne l'administration de leucine-5-enképhaline encapsulée dans du GCPQ par voie intranasale par l'intermédiaire d'un médicament ou d'une dispersion de médicament et d'un système d'administration. Les procédés de dispersion utilisent des surfaces incurvées pour conférer des mouvements de rotation à un ou à plusieurs écoulements de fluide depuis un récipient sous pression pour créer une turbulence et améliorer le mélange d'un médicament avec un fluide.